Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

@article{Lazzarin2003EfficacyOE,
  title={Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia},
  author={Adriano Lazzarin and Bonaventura Clotet and David Cooper and J. Reynes and Keikawus Arast{\'e}h and Mark Nelson and Christine Katlama and Hans-J{\"u}rgen Stellbrink and J F Delfraissy and Josephus H. M. Lange and Les Huson and Ralph Demasi and Cynthia Wat and John T. Delehanty and Claude Drobnes and Miklos P Salgo},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 22},
  pages={
          2186-95
        }
}
BACKGROUND The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks of treatment with the fusion inhibitor enfuvirtide in combination with an optimized background antiretroviral regimen with the efficacy and safety of the optimized background regimen alone. METHODS The patients had previous treatment with each of the three classes of antiretroviral drugs, documented resistance to each class, or both and a plasma level of human immunodeficiency virus… CONTINUE READING
Highly Cited
This paper has 232 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 114 extracted citations

The discovery and development of antiretroviral agents.

Antiviral therapy • 2014
View 4 Excerpts
Method Support
Highly Influenced

Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale • 2010
View 10 Excerpts
Highly Influenced

Enfuvirtide, a new treatment for HIV infection.

Issues in emerging health technologies • 2003
View 5 Excerpts
Highly Influenced

Nuevas dianas y nuevos fármacos en el tratamiento de la infección por el VIH

José López-Aldeguera, Koldo Aguirrebengoab, José Ramón Arribasc, José A. Estéd, José María Kindeláne
2018

232 Citations

0102030'03'06'10'14'18
Citations per Year
Semantic Scholar estimates that this publication has 232 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Clinical and laboratory guidelines for the use of HIV - 1 drug resistance testing as part of treatment management : recommendations for the European setting

SM Hammer, F Vaida, KK Bennett
AIDS • 2001

Determinants of virological response to antiretroviral therapy: implications for long-term strategies.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2000

Prevalence and characteristics of multinucleoside - resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

K VanVaerenbergh, K VanLaethem
Antimicrob Agents Chemother • 2000